Truncating mutations in FLNC (filamin-C), a cytoskeletal scaffolding protein, are increasingly recognized and associated with high arrhythmic risk, frequent myocardial fibrosis, and a relatively poor prognosis, even in the presence of modest ventricular dysfunction [142], supporting early device implantation irrespective of LVEF, particularly when late gadolinium enhancement (LGE) is present on CMR imaging [137,142]. The gene discussed is FLNC; the disease is Myocardial fibrosis.